Zilretta for Osteoarthritis, Knee

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Ohio State Outpatient Lewis Center, Lewis Center, OH
Osteoarthritis, Knee+1 More
Zilretta - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.

Eligible Conditions

  • Osteoarthritis, Knee

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Osteoarthritis, Knee

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Baseline, 3 month, 6 month

6 month
Knee injury and Osteoarthritis Outcome Score (KOOS) Pain patient reported outcome questionnaire
Baseline, 3 month
Knee injury and Osteoarthritis Outcome Score (KOOS) Pain patient reported outcome
Month 6
Knee injury and Osteoarthritis Outcome Score (KOOS) Function in Sport and Recreation (Sport/Rec) patient reported outcome
Knee injury and Osteoarthritis Outcome Score (KOOS) Function in daily living (ADL) patient reported outcome
Knee injury and Osteoarthritis Outcome Score (KOOS) Symptoms patient reported outcome
Knee injury and Osteoarthritis Outcome Score (KOOS) knee related quality of life (QOL) patient reported outcome

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Osteoarthritis, Knee

Trial Design

3 Treatment Groups

Zilretta
1 of 3
Synvisc One
1 of 3
Monovisc
1 of 3
Active Control

165 Total Participants · 3 Treatment Groups

Primary Treatment: Zilretta · No Placebo Group · Phase 4

Zilretta
Drug
ActiveComparator Group · 1 Intervention: Zilretta · Intervention Types: Drug
Synvisc One
Drug
ActiveComparator Group · 1 Intervention: Synvisc-One 48 MG in 6 ML Prefilled Syringe · Intervention Types: Drug
Monovisc
Drug
ActiveComparator Group · 1 Intervention: Monovisc 88 MG Per 4 ML Prefilled Syringe · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 3 month, 6 month

Trial Background

Prof. Michael Baria, Associate Professor
Principal Investigator
Ohio State University
Closest Location: Ohio State Outpatient Lewis Center · Lewis Center, OH
N/AFirst Recorded Clinical Trial
1 TrialsResearching Osteoarthritis, Knee
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of unilateral knee OA.
You have radiographic evidence of OA of the target knee.
You have KOOS-Pain subscale 20-65.
You are able to read and write in English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.